Fig. 1.

SMARCA4 expression correlates with NE features in SCLC. A SMARCA4 mRNA levels in cell lines derived from 30 tumor types assessed using the Cancer Cell Line Encyclopedia (CCLE). Bars indicate the median expression per tumor type. B SMARCA4 mRNA levels in LUAD and SCLC specimens retrieved from Quintanal Villalonga et al. [27]. Student’s two-tailed unpaired t test. **p < 0.01. C Spearman correlation of SYP, CHGA, INSM1, YAP1 and REST with SMARCA4 mRNA levels in Rudin et al. and George et al. databases and CCLE[25, 26]. D SMARCA4 mRNA expression in low and high NE SCLC tumors in cell lines (CCLE) and clinical specimens (Rudin et al. and George et al.) [25, 26]. One-way ANOVA test followed by Bonferroni post-hoc test. ****p < 0.0001, ***p < 0.001, **p < 0.01. E Western blotting of ASCL1, NEUROD1, SYP and CHGA in isogenic cell lines derived from H82 and H146 expressing different combinations of shRNAs against SMARCA4 and/or SMARCA2. Expression of shRNAs from E was conditional of doxycycline treatment. Protein collection and blotting was performed after 14 days of doxycycline treatment. See also Fig. S1